Q2 2026 saw strong sales and profit growth, led by Hi-Tech E&C and robust trading, with operating margin and order backlog both improving. Biologics announced a major acquisition, and the company is expanding in nuclear, SMR, and data centers. Dividend policy focuses on cash payouts from affiliate income.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.